RESUMO
Active learning assignments can be achieved in online discussions, resulting in creative linkages for innovation. This article describes how the teaching strategy of active learning assignment evolved into a group of student learners engaging in the development of a creative advanced clinical care scenario in an online graduate core course on leadership and management. The advanced clinical scenario that resulted from the students envisioning the assignment through the continuum of care was innovative and creative. Most importantly, the scenario stimulated vigorous conversation and excitement over the assignment, which promoted learning, pride in accomplishment, and on-the-job impact. This article serves as a model of ways to engage students in active learning for synthesis and evaluation to enable creativity and innovation.
Assuntos
Instrução por Computador/métodos , Currículo , Educação de Pós-Graduação em Enfermagem/métodos , Pessoal de Saúde/educação , Liderança , Aprendizagem Baseada em Problemas , Cuidado Transicional/organização & administração , Adulto , Feminino , Humanos , Internet , Masculino , Pessoa de Meia-Idade , Estados UnidosRESUMO
BACKGROUND: The authors performed a phase 2 study of bevacizumab plus pemetrexed and carboplatin followed by maintenance bevacizumab in patients with advanced, nonsquamous nonsmall cell lung cancer. METHODS: Previously untreated patients with advanced, nonsquamous nonsmall cell lung cancer and an Eastern Cooperative Oncology Group performance status of 0 or 1 received bevacizumab 15 mg/kg, pemetrexed 500 mg/m(2) and carboplatin at an area under the concentration-time curve of 6 intravenously on day 1 every 21 days. Responding or stable patients who completed 6 cycles then received bevacizumab maintenance every 21 days until disease progression. RESULTS: In total, 43 patients (40 who were evaluable for response) were entered on the study. Treatment-related grade 3/4 toxicities were low and included febrile neutropenia (2%), neutropenia (28%), anemia (18%), thrombocytopenia (11%), hypertension (7%), epistaxis (5%), venous thrombosis (8%), dyspnea (7%), rectovaginal fistula (2.3%), infusion reaction (2%), and cerebrovascular event (2%). One patient died from complications of venous thromboembolism and cerebrovascular accident after Cycle 2. Minimal clinically significant toxicity occurred during maintenance bevacizumab. Two complete responses (5%) were observed, and 17 patients (42%) had a partial response. Fifteen patients (38%) displayed disease stability. The overall disease control rate was 85%. At a median follow-up of 15.8 months, the median progression-free survival was 7.1 months (95% confidence interval, 5.9-8.3 months), and the median overall survival was 17.1 months (95% confidence interval, 8.8-25.5 months). CONCLUSIONS: Combined bevacizumab, pemetrexed, and carboplatin followed by maintenance bevacizumab was well tolerated and displayed remarkable activity in patients with previously untreated, advanced, nonsquamous nonsmall cell lung cancer.